Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

about

Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

Item

http://www.wikidata.org/entity/Q38398014

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

@en

type

Item

label

Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

@en

prefLabel

Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

@en

P1476

Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.

@en

P2093

Chandrasekar Palaniswamy

http://www.w3.org/2001/XMLSchema#string

Jalaj Garg

http://www.w3.org/2001/XMLSchema#string

Larry E Jacobs

http://www.w3.org/2001/XMLSchema#string

Martin Zak

http://www.w3.org/2001/XMLSchema#string

Saramaria Afanador Castiblanco

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study.

Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Dabigatran etexilate: a new oral thrombin inhibitor.

Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.

Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.

P304

457-464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1074248415576193

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25827857

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation